Atara Biotherapeutics (ATRA) Investor Presentation - Slideshow

ATA188 and Multiple Sclerosis (MS) - ATA188 is an allogeneic T cell therapy targeting Epstein-Barr virus (EBV), the underlying cause of MS[6] - Phase 1 data supports the safety and potential for transformative disability improvement in progressive MS with ATA188[6] - Recent publications identify EBV as the leading cause of MS[7] - In a Phase 1/OLE study, 20 out of 24 patients with non-active progressive MS showed improvement or stability with EDSS[7] - The company plans to conduct a formal interim analysis in Q2 2022 to optimize the likelihood of success in Phase 2[7] EBV and MS - Up to 100% of MS patients are EBV seropositive[55] - A 2022 study showed a 32-fold increase in the risk of MS after EBV infection[58] - EBV proteins bind risk loci mapped to many autoimmune diseases, including MS[114] Clinical Trial and Data - In Phase 1 study, 33% confirmed EDSS improvement in Cohorts 3 – 4 at 12 Months[75] - Analysis of placebo data shows limited placebo-driven EDSS improvement, around 5% in non-active PMS[100] - The company is currently enrolling 80 non-active progressive MS patients in the ATA188 Phase 2 Randomized, Placebo-Controlled Study (EMBOLD)[99] Manufacturing and Commercial Potential - Scaled-up manufacturing process planned to result in the ability to produce up to ~20,000 doses from one donor collection[108] - Current inventory model projects coverage of ~95% of MS patients with ~10 HLA specific product lots[108] - ATA188 has the potential to be a transformative multi-billion dollar opportunity[122]